Cargando…

First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate

BACKGROUND: The first wave of SARS-CoV-2 infection in Chile occurred during the cold season reaching a peak by the end of June 2020, with 80 % of the cases concentrated in its capital, Santiago. The main objective of this study was to estimate the attack rate during this first wave of SARS-CoV-2 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Vial, Pablo A., González, Claudia, Apablaza, Mauricio, Vial, Cecilia, Lavín, M.Estela, Araos, Rafael, Rubilar, Paola, Icaza, Gloria, Florea, Andrei, Pérez, Claudia, Concha, Paula, Bastías, Diego, Errázuriz, María Paz, Pérez, Ruth, Guzmán, Francisco, Olea, Andrea, Guzmán, Eugenio, Correa, Juan, Munita, José Manuel, Aguilera, Ximena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277990/
https://www.ncbi.nlm.nih.gov/pubmed/35872438
http://dx.doi.org/10.1016/j.epidem.2022.100606
_version_ 1784746104136400896
author Vial, Pablo A.
González, Claudia
Apablaza, Mauricio
Vial, Cecilia
Lavín, M.Estela
Araos, Rafael
Rubilar, Paola
Icaza, Gloria
Florea, Andrei
Pérez, Claudia
Concha, Paula
Bastías, Diego
Errázuriz, María Paz
Pérez, Ruth
Guzmán, Francisco
Olea, Andrea
Guzmán, Eugenio
Correa, Juan
Munita, José Manuel
Aguilera, Ximena
author_facet Vial, Pablo A.
González, Claudia
Apablaza, Mauricio
Vial, Cecilia
Lavín, M.Estela
Araos, Rafael
Rubilar, Paola
Icaza, Gloria
Florea, Andrei
Pérez, Claudia
Concha, Paula
Bastías, Diego
Errázuriz, María Paz
Pérez, Ruth
Guzmán, Francisco
Olea, Andrea
Guzmán, Eugenio
Correa, Juan
Munita, José Manuel
Aguilera, Ximena
author_sort Vial, Pablo A.
collection PubMed
description BACKGROUND: The first wave of SARS-CoV-2 infection in Chile occurred during the cold season reaching a peak by the end of June 2020, with 80 % of the cases concentrated in its capital, Santiago. The main objective of this study was to estimate the attack rate during this first wave of SARS-CoV-2 in a large, densely populated city with more than seven million inhabitants. Since the number of confirmed cases provides biased information due to individuals' potential self-selection, mostly related to asymptomatic patients and testing access, we measured antibodies against SARS-CoV-2 to assess infection prevalence during the first wave in the city, as well as estimate asymptomatic cases, and infection fatality ratio. To our knowledge this is one of the few population-based cross-sectional serosurvey during the first wave in a highly affected emerging country. The challenges of pandemic response in urban settings in a capital city like Santiago, with heterogeneous subpopulations and high mobility through public transportation, highlight the necessity of more accurate information regarding the first waves of new emerging diseases. METHODS: From April 24 to June 21, 2020, 1326 individuals were sampled from a long-standing panel of household representatives of Santiago. Immunochromatographic assays were used to detect IgM and IgG antibody isotypes. RESULTS: Seroprevalence reached 6.79 % (95 %CI 5.58 %−8.26 %) in the first 107 days of the pandemic, without significant differences among sex and age groups; this figure indicates an attack rate 2.8 times higher than the one calculated with registered cases. It also changes the fatality rate estimates, from a 2.33 % case fatality rate reported by MOH to an estimated crude 1.00 % (CI95 % 0.97–1.03) infection fatality rate (adjusted for test performance 1.66 % [CI95 % 1.61–1.71]). Most seropositive were symptomatic (81,1 %). CONCLUSIONS: Despite the high number of cases registered, mortality rates, and the stress produced over the health system, the vast majority of the people remained susceptible to potential new epidemic waves. We contribute to the understanding of the initial spread of emerging epidemic threats. Consequently, our results provide better information to design early strategies that counterattack new health challenges in urban contexts.
format Online
Article
Text
id pubmed-9277990
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-92779902022-07-14 First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate Vial, Pablo A. González, Claudia Apablaza, Mauricio Vial, Cecilia Lavín, M.Estela Araos, Rafael Rubilar, Paola Icaza, Gloria Florea, Andrei Pérez, Claudia Concha, Paula Bastías, Diego Errázuriz, María Paz Pérez, Ruth Guzmán, Francisco Olea, Andrea Guzmán, Eugenio Correa, Juan Munita, José Manuel Aguilera, Ximena Epidemics Article BACKGROUND: The first wave of SARS-CoV-2 infection in Chile occurred during the cold season reaching a peak by the end of June 2020, with 80 % of the cases concentrated in its capital, Santiago. The main objective of this study was to estimate the attack rate during this first wave of SARS-CoV-2 in a large, densely populated city with more than seven million inhabitants. Since the number of confirmed cases provides biased information due to individuals' potential self-selection, mostly related to asymptomatic patients and testing access, we measured antibodies against SARS-CoV-2 to assess infection prevalence during the first wave in the city, as well as estimate asymptomatic cases, and infection fatality ratio. To our knowledge this is one of the few population-based cross-sectional serosurvey during the first wave in a highly affected emerging country. The challenges of pandemic response in urban settings in a capital city like Santiago, with heterogeneous subpopulations and high mobility through public transportation, highlight the necessity of more accurate information regarding the first waves of new emerging diseases. METHODS: From April 24 to June 21, 2020, 1326 individuals were sampled from a long-standing panel of household representatives of Santiago. Immunochromatographic assays were used to detect IgM and IgG antibody isotypes. RESULTS: Seroprevalence reached 6.79 % (95 %CI 5.58 %−8.26 %) in the first 107 days of the pandemic, without significant differences among sex and age groups; this figure indicates an attack rate 2.8 times higher than the one calculated with registered cases. It also changes the fatality rate estimates, from a 2.33 % case fatality rate reported by MOH to an estimated crude 1.00 % (CI95 % 0.97–1.03) infection fatality rate (adjusted for test performance 1.66 % [CI95 % 1.61–1.71]). Most seropositive were symptomatic (81,1 %). CONCLUSIONS: Despite the high number of cases registered, mortality rates, and the stress produced over the health system, the vast majority of the people remained susceptible to potential new epidemic waves. We contribute to the understanding of the initial spread of emerging epidemic threats. Consequently, our results provide better information to design early strategies that counterattack new health challenges in urban contexts. The Author(s). Published by Elsevier B.V. 2022-09 2022-07-13 /pmc/articles/PMC9277990/ /pubmed/35872438 http://dx.doi.org/10.1016/j.epidem.2022.100606 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Vial, Pablo A.
González, Claudia
Apablaza, Mauricio
Vial, Cecilia
Lavín, M.Estela
Araos, Rafael
Rubilar, Paola
Icaza, Gloria
Florea, Andrei
Pérez, Claudia
Concha, Paula
Bastías, Diego
Errázuriz, María Paz
Pérez, Ruth
Guzmán, Francisco
Olea, Andrea
Guzmán, Eugenio
Correa, Juan
Munita, José Manuel
Aguilera, Ximena
First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate
title First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate
title_full First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate
title_fullStr First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate
title_full_unstemmed First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate
title_short First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate
title_sort first wave of sars-cov-2 in santiago chile: seroprevalence, asymptomatic infection and infection fatality rate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277990/
https://www.ncbi.nlm.nih.gov/pubmed/35872438
http://dx.doi.org/10.1016/j.epidem.2022.100606
work_keys_str_mv AT vialpabloa firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT gonzalezclaudia firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT apablazamauricio firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT vialcecilia firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT lavinmestela firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT araosrafael firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT rubilarpaola firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT icazagloria firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT floreaandrei firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT perezclaudia firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT conchapaula firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT bastiasdiego firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT errazurizmariapaz firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT perezruth firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT guzmanfrancisco firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT oleaandrea firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT guzmaneugenio firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT correajuan firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT munitajosemanuel firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate
AT aguileraximena firstwaveofsarscov2insantiagochileseroprevalenceasymptomaticinfectionandinfectionfatalityrate